• NHT210118

  The Class I new drug biological product in China in Project NHT210118 of Novel Peptide Bioscience Co., Ltd. is a therapeutic vaccine that has been clinically validated to "regulate immune response through mimogen to achieve immunotherapy", and the immunization schedule, response characteristics, safety and efficacy of the vaccine regimen have been basically determined and the Phase II clinical study has been completed. Now, we are recruiting subjects to participate in Phase III clinical trial with the specific therapy for viral hepatitis B as the target.

Please look forward to more products.